Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study-Reference-Cited by-同舟云学术

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

Published:2013-01 Issue:1 Volume:14 Page:38-47
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Jänne Pasi A,Shaw Alice T,Pereira José Rodrigues,Jeannin Gaëlle,Vansteenkiste Johan,Barrios Carlos,Franke Fabio Andre,Grinsted Lynda,Zazulina Victoria,Smith Paul,Smith Ian,Crinò Lucio

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Crinó;Ann Oncol,2010

3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 574 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

2. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer;Signal Transduction and Targeted Therapy;2024-08-21

3. Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients;Cancers;2024-08-07

4. The safety and efficacy of binimetinib for lung cancer: a systematic review;BMC Pulmonary Medicine;2024-08-01

5. In vitro inhibitory effects of selumetinib on activity of human UDP-glucuronosyltransferases and prediction of in vivo drug-drug interactions;Toxicology in Vitro;2024-08